Mark Pimentel, MD, discusses the release of a new blood test that may aid in the diagnosis of scleroderma and systemic sclerosis.
Connective Tissue Disease
Although pulmonary arterial hypertension occurs in a minority of patients with systemic sclerosis, clinicians must be attentive to it, as it can emerge at any point over the course of the disease.
Addressing the challenges associated with clinical management of calcium pyrophosphate crystal deposition must start with understanding the unmet needs of associated joint damage and establishing a clearly defined strategy to address these needs.
A patient with a history of uncontrolled gout presents with highly refractile, crystal-like macular lesions.
Assessing the relationship between gout and the metabolic syndrome may provide insight into the management of both conditions.
A thorough work-up can differentiate between primary and secondary forms, mitigating progression of a more severe underlying disease.
As part of Scleroderma Awareness Month, physicians specializing in the management of scleroderma discuss mitigating effects of scleroderma-related pain and improving quality of life for their patients.
Inflammatory ganglionopathies can be associated with good clinical outcomes if treatments are administered in a timely manner.
If conservative treatment with medications such as dihydropyridine, calcium channel blockers, alpha-adrenergic blockers, and phosphodiesterase-5 inhibitors is unsuccessful, clinicians can consider chemical sympathectomy, botulinum neurotoxin injection, and fat pad grafting.